Subtype
Primary Brain Neoplasm
CI-CAN-00003725Explore in graph →
Non-malignant157 active trials34 evidence items
- NCIt
- C170814
Loading cancer entity…
Subtype
CI-CAN-00003725Explore in graph →
Clinical trials
509 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 |
| clinicaltrials |
| NCT06193759 | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) | recruiting | Phase 1 | 12 | Children's National Research InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06914479 | Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors | recruiting | Phase 1 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03224767 | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | active not recruiting | Phase 2 | 24 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT00085735 | Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma | completed | Phase 3 | 549 | Children's Oncology GroupNETWORK | 7 | Jun 9, 2026 | clinicaltrials |
| NCT00392327 | Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET | completed | Phase 3 | 379 | Children's Oncology GroupNETWORK | 5 | Jun 8, 2026 | clinicaltrials |
| NCT04911621 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma(ADDICT-pedGLIO) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02875314 | HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors | active not recruiting | Phase 4 | 250 | Parth PatelOTHER | 3 | Jun 3, 2026 | clinicaltrials |
| NCT03033992 | Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | active not recruiting | N/A | 80 | Children's Oncology GroupNETWORK | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07617168 | The Effect of Education Brain Tumors(Education&BT) | recruiting | N/A | 72 | Istanbul University - CerrahpasaOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05979064 | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | recruiting | N/A | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05116137 | The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors(RESIST) | enrolling by invitation | N/A | 24 | Nova Scotia Health AuthorityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT07608003 | Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: | recruiting | — | 500 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT02860923 | Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy(CRANIOEXE) | completed | Phase 3 | 42 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07479446 | Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery | recruiting | N/A | 174 | Xuanwu Hospital, BeijingOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04087902 | Long-Term Longitudinal QoL in Patients Undergoing EEA | active not recruiting | — | 400 | Ohio State UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07589257 | A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma | recruiting | Phase 2 | 10 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07589361 | Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors(VBS-CSI-PT-PED) | not yet recruiting | — | 38 | Ruijin HospitalOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | completed | Phase 3 | 479 | Children's Oncology GroupNETWORK | 4 | Apr 30, 2026 | clinicaltrials |
| NCT07017816 | A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.(JACOB) | recruiting | Early Phase 1 | 18 | Children's National Research InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05128903 | Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study | active not recruiting | Phase 2 | 22 | St. Jude Children's Research HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05233397 | ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 30 | Nationwide Children's HospitalOTHER | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05465174 | Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults(PNOC029) | recruiting | Phase 2 | 57 | Sabine Mueller, MD, PhDOTHER | 2 | Apr 23, 2026 | clinicaltrials |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | terminated | — | 57 | Pediatric Brain Tumor ConsortiumNETWORK | 2 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04670016 | HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers | completed | — | 20 | University of CalgaryOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 38 | Nationwide Children's HospitalOTHER | 3 | Apr 8, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03610906 | Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy | enrolling by invitation | — | 250 | University of Colorado, DenverOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | active not recruiting | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials